AU2002352941A1 - Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer - Google Patents

Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer Download PDF

Info

Publication number
AU2002352941A1
AU2002352941A1 AU2002352941A AU2002352941A AU2002352941A1 AU 2002352941 A1 AU2002352941 A1 AU 2002352941A1 AU 2002352941 A AU2002352941 A AU 2002352941A AU 2002352941 A AU2002352941 A AU 2002352941A AU 2002352941 A1 AU2002352941 A1 AU 2002352941A1
Authority
AU
Australia
Prior art keywords
administered
amount
day
fpt inhibitor
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002352941A
Other languages
English (en)
Inventor
Charles Baum
David L Cutler
Michael L Meyers
Sara L Zaknoen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002352941A1 publication Critical patent/AU2002352941A1/en
Priority to AU2007201079A priority Critical patent/AU2007201079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002352941A 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer Abandoned AU2002352941A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007201079A AU2007201079A1 (en) 2001-11-30 2007-03-13 Methods of treating cancer using an FPT inhibitor and antineoplastic agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334,411 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007201079A Division AU2007201079A1 (en) 2001-11-30 2007-03-13 Methods of treating cancer using an FPT inhibitor and antineoplastic agents

Publications (1)

Publication Number Publication Date
AU2002352941A1 true AU2002352941A1 (en) 2003-06-17

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002352941A Abandoned AU2002352941A1 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Country Status (13)

Country Link
US (2) US20030185831A1 (enExample)
EP (1) EP1448268A2 (enExample)
JP (1) JP2005511663A (enExample)
CN (2) CN1617755A (enExample)
AU (1) AU2002352941A1 (enExample)
BR (1) BR0214564A (enExample)
CA (1) CA2468839A1 (enExample)
HU (1) HUP0402401A2 (enExample)
MX (1) MXPA04005207A (enExample)
NO (1) NO20042730L (enExample)
NZ (1) NZ532562A (enExample)
WO (1) WO2003047697A2 (enExample)
ZA (1) ZA200403737B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
AU2004289256A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
JP2010507662A (ja) * 2006-10-25 2010-03-11 シェーリング コーポレイション 癌の処置のための不連続方法
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
EP4615842A1 (en) 2022-11-09 2025-09-17 Merck Patent GmbH Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
BR0114430A (pt) * 2000-10-05 2004-01-06 George Q Daley Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Also Published As

Publication number Publication date
CN101181269A (zh) 2008-05-21
NO20042730L (no) 2004-06-29
WO2003047697A3 (en) 2003-10-30
ZA200403737B (en) 2005-05-23
BR0214564A (pt) 2004-11-09
MXPA04005207A (es) 2004-08-19
US20030185831A1 (en) 2003-10-02
HUP0402401A2 (hu) 2005-03-29
CN1617755A (zh) 2005-05-18
EP1448268A2 (en) 2004-08-25
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23
CA2468839A1 (en) 2003-06-12
WO2003047697A2 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
JP2021059564A (ja) 癌治療のための併用療法
EP2609920A1 (en) Method of treating cancer by a combined therapy of YM-155 with other anticancer agents
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
EP4506004A1 (en) Pharmaceutical composition, use thereof, and method for treating cancer
HUP0301690A2 (hu) Szinergikus eljárások és készítmények rák kezelésére
KR20090040926A (ko) 암 치료용 배합 생성물
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2003533485A5 (enExample)
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
US20030185831A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic
KR20080100838A (ko) (2ｒ,ｚ)-2-아미노-2-사이클로헥실-ｎ-(5-(1-메틸-1ｈ-피라졸-4-일)-1-옥소-2,6-다이하이드로-1ｈ-[1,2]다이아제피노[4,5,6-ｃｄ]인돌-8-일)아세트아미드의 복합 요법
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
JP2005511663A5 (enExample)
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN119326902A (zh) 癌症联合治疗的组合物与方法
US20050267140A1 (en) Method for treating abnormal cell growth
WO2020020155A1 (en) IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
Haglof et al. Recent developments in the clinical activity of topoisomerase-1 inhibitors
MX2007013830A (es) Terapia de combinacion.
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
CN120154734A (zh) 维奈克拉联合瑞戈非尼在治疗急性髓系白血病中的应用
Von Pawel Topotecan (Hycamtin®): potent cytostatic action by selective topoisomerase I inhibition

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted